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Detection of abnormally elevated levels of molecules in patients with oral cancer may be useful in early diagnosis. These markers can be included in current Histopathology 
grading and in TNM staging systems of Oral Squamous Cell Carcinoma (OSCC) to make it 
more ef¿cient. Several pro-angiogenic molecules have been assessed for the same reason. 
Endothelin-1 (ET-1) is a vasoactive peptide associated with the development and spread of 
many solid tumors, including Squamous Cell Carcinoma (SCC), but its utility in OSCC has 
not been con¿rmed. ObMective: This study aims to evaluate the role of the serum big ET-1 
as a biomarker of OSCC, by correlating it with the clinical staging and the histopathological 
grading. Material and Methods: Serum levels of big ET-1 measured by the sandwich Enzyme-
Linked Immunosorbent Assay (ELISA) in 40 OSCC cases were compared with the levels from 
the control group using independent t-test. Clinical stages and histopathological grades of 
OSCC cases were compared in relation to their mean levels of serum big ET-1, one using 
the Analysis of Variance (ANOVA) test and the other the independent t-test, respectively. 
The signi¿cance of the mean difference between the groups was evaluated by Tukey¶s 
multiple comparison test. All statistical analyses were performed on GraphPad statistical 
software version 5.0. Results: By comparing the mean of the big ET-1 concentrations of 
cases and controls, the independent t-test revealed signi¿cant higher big ET-1 concentration 
of OSCC cases when compared to controls (p<0.0001). Tukey’s multiple comparison test 
also revealed statistically signi¿cant difference among all OSCC stages in relation to the 
mean levels of serum big ET-1. However, the mean of the big ET-1 concentrations of cases 
of grade I and of grade II did not differ statistically (p=0.729). Conclusion: Serum big 
ET-1 levels may be useful as a diagnostic tool in OSCC and as an adjunct to OSCC staging. 
However, its use as a prognostic marker warrants larger prospective studies.
Keywords: Endothelin-1. Oral cancer. Cancer staging. Neoplasm grading.
INTRODUCTION
Oral cancer is the 6th most common cancer in 
the world. India is the highest ranked country in 
the world with over 1,00,000 cases per year with 
mortality rate of 22.9%, which is largely attributed 
to the late diagnosis of the disease33.  However, 
Histopathology remains the gold standard for the 
diagnose of oral cancer; the grade of differentiation 
alone shows poor correlation with the outcome 
and the response to treatment of an individual 
patient13. Also the TNM clinical staging does not 
provide suf¿cient predictive information on the 
optimal treatment bene¿cial for each patient24. 
This is attributed to the different biological 
behavior of patients with OSCC with similar clinico-
pathologic features and results in higher morbidity 
and mortality rate despite some advances in 
treatment. Marked prognostic variability exhibited 
by individual tumors arising from the same site 
and having identical histological tumor grade 
warrants additional parameters to classify the tumor 
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more precisely in terms of its aggressiveness and 
biology10.
Interest in the role of ET-1 as an angiogenic 
molecule in cancer has grown over the last two 
decades, following the demonstration of ET-1 
production by several tumor cell lines5,8,14,21. The 
contribution of ET-1 in tumor growth and progression 
has been evaluated in prostatic, ovarian, renal, 
pulmonary, colorectal, cervical, breast, lung, 
bladder, and endometrial cancer1,4,14,17,29-31. In the 
context of oral tissues, it has been demonstrated 
that keratinocytes can translate and secrete ET-1 
protein into the keratinocyte conditioned medium 
and oral epithelial cell line can produce ET-134,35. 
ET-1 levels from culture supernatants of human 
oral SCC cell lines were found to be higher when 
compared to the one of normal human epidermal 
keratinocytes6. This study also demonstrated 
that OSCC cells possess the required machinery 
to synthesize and secrete ET-1. They suggested 
that ET-1 may act in an autocrine manner on 
oral SCC cells, promoting their growth, and in 
paracrine manner on endothelial cells and oral 
¿broblasts assisting tumor growth and invasion6. 
Currently there is evidence that ET-1 contributes 
to carcinogenesis directly through proliferation, 
resistance to apoptosis, migration, and invasion 
while indirectly through angiogenesis, Extracellular 
Matrix (ECM) breakdown and deposition14,19. Thus, 
the ET-1 presents itself as a promising biomarker 
in OSCC. Therefore, this study was designed to 
assess the use of serum big ET-1 as a biomarker 
of oral SCC, correlating it with clinical staging and 
histopathological grading.
MATERIAL AND METHODS
This study was approved by the Institutional 
Ethics Committee,  including a total of 80 subjects 
and being composed of a study group of 40 patients 
histopathologically diagnosed with Oral Squamous 
Cell Carcinoma (OSCC) and a control group of age 
40 and with healthy and sex matched subjects. 
Patients who had received or were receiving any 
treatment for carcinoma and patients with known 
systemic illness or with any other oral disease were 
excluded from the study. Demographic and clinical 
features of OSCC cases have been given in Table 
1. Informed consent was obtained from all patients 
and control participants.
The diagnosis of squamous cell carcinoma was 
con¿rmed in each case by the histopathological 
examination of an incisional biopsy in the 
representative site of the lesion. The relevant 
history of each patient was done and recorded 
through clinical examination to rule out any 
systemic illness or any other local disease or 
prior therapy. Clinical staging of patients with 
oral squamous cell carcinoma was performed 
according to the TNM classi¿cation given by the 
American Joint Committee on Cancer (AJCC) for 
Staging Atlas15 (2006) and End Results Reporting13. 
The histopathological grading of oral squamous 
cell carcinoma was performed according to the 
malignancy grading system proposed by Anneroth, 
et al.2 (1987). This grading system is consisted of 
six parameters: degree of keratinization, nuclear 
polymorphism, number of mitoses per high power 
¿eld, pattern of invasion, stage of invasion, and 
lympho-plasmacytic in¿ltration. Each parameter 
was graded from 1 to 4 points. As recommended 
by Araújo, et al.3 (1997), the parameter “stage of 
invasion” was omitted as incisional biopsy was used 
for histopathological grading of OSCC. Total scores 
for malignancy histological grading were obtained 
by the sum of the scores given for each parameter, 
and then divided by the number of parameters 
used. The ¿nal grading was done as follows: 1.0 
to 2.0 – Grade I; 2.1 to 3.0 – Grade II, and 3.1 to 
4.0 – Grade III.
From each subject, 5 ml of intravenous blood 
was collected using an evacuated blood collection 
system (Becton, Dickinson and Company, Franklin 
Lakes, New Jersey, USA). Then, the blood was 
allowed to clot at room temperature for about 2 
hours and then centrifuged at 3000 RPM for 10 
minutes to separate the serum for the study. The 
concentrations of serum big ET-1 were estimated in 
both cases and controls by the solid phase sandwich 
ELISA (Immuno-Biological Laboratories Co. Ltd., 
Fujioka-Shi, Gunma, Japan).
Statistical analysis
The mean levels of serum big ET-1 among 
the study and the control group was compared 
by the independent t-test. The ANOVA test and 
independent t-test were applied respectively to 
compare clinical stages and histopathological 
grades of  OSCC cases in relation to their mean 
levels of serum big ET-1. The signi¿cance of the 
difference between the means of groups was 
evaluated by Tukey’s multiple comparison test. All 
statistical analyses were performed using GraphPad 
Prism v.5.0 software. All p-values of <0.05 were 
considered statistically signi¿cant.
RESULTS
The age of the cases and controls of OSCC ranged 
from 27-72 years and from 25-74 years, respectively, 
with mean (±SD) values of 54.68±12.95 years and 
53.7±13.17 years, respectively. The peak incidence 
of oral squamous cell carcinoma was noted in the 
7th decade of life among the cases OSCC. However, 
in sex-wise distribution, peak incidence was seen in 
the 7th decade of life in females, while it was equal 
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in the 5th and in the 7th decade of life in males. In the present study, 11 (27.5%) patients were 45 
Clinicopathologic 
variables
No. of patients Mean serum big 
ET-1 levels in pg/ml 
(Mean±SD)
Value of p 6LJQL¿FDQFH
Age
21-30 2 (5%) 4.23±1.01 0.6064 QRWVLJQL¿FDQW
31-40 7 (18%) 4.41±0.62
41-50 9 (22.5%) 4.35±0.53
51-60 5 (12.5%) 4.08±0.26
61-70 14 (35%) 4.76±0.92
71-80 3 (7%) 4.50±1.37
Gender
Male 26 (65%) 4.35±0.80 0.1734 QRWVLJQL¿FDQW
Female 14 (35%) 4.70±0.68
Anatomic Site
Alveolar mucosa 13 (32.5%) 4.35±0.82 0.063 QRWVLJQL¿FDQW
Buccal mucosa 8 (20%) 4.83±0.65
Tongue 6 (15%) 3.81±0.54
GB complex 6 (15%) 4.85±0.58
Palate 2 (5%) 4.74±0.62
Multifocal 2 (5%) 5.12±0.49
Clinical Staging
Stage I 3 (7.5%) 2.81±0.23  KLJKO\VLJQL¿FDQW
Stage II 7 (17.5%) 3.72±0.22
Stage III 13 (32.5%) 4.47±0.40
Stage IV 17 (42.5%) 5.07±0.40
Histopathological 
Grading
Grade I 36 (90%) 4.40±0.77 0.727 QRWVLJQL¿FDQW
Grade II 4 (10%) 5.12±0.18
Table 1- Comparison of clinico pathologic variables of OSCC cases with serum big ET-1 levels
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Figure 1- Comparison of mean levels of big ET-1 between oral squamous cell carcinoma (OSCC) cases and controls using 
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years and the remaining 29 (72.5%) were above 
45 years. Male: female ratio of the OSCC cases was 
1.8:1.There was no signi¿cant difference among 
groups of different age (p=0.6064 ) and gender 
(p=0.1734) in relation to the serum big ET-1 values 
analyzed by the ANOVA test and the independent 
t-test, respectively (Table 1). The alveolar mucosa 
was the most common site (32.5%) to be involved 
in patients with OSCC, followed by the buccal 
mucosa (20.0%), the tongue (15.0%), and the 
gingivobuccal complex (15.0%). Comparing the 
mean of the big ET-1 concentration between the 
sites, ANOVA revealed no signi¿cant difference 
(p=0.063) (Table 1). The mean big ET-1 level in 
multifocal lesions and in the gingivobuccal complex 
were the highest, the lowest being the mean for 
tongue.
Comparing the mean big ET-1 concentrations 
of the two groups, the independent t-test revealed 
a signi¿cantly higher big ET-1 concentration in 
OSCC cases when compared to controls (p<0.0001, 
t=11.37) (Figure 1). Furthermore, intragroup 
comparison of the mean levels of serum big ET-1 
by Tukey’s multiple comparison test also revealed 
statistically signi¿cant difference among all OSCC 
stages (Figure 2). However, the mean of big ET-1 
concentrations of cases of grade I of OSCC and of 
OSCC grade II did not differ statistically (p=0.729) 
(Figure 3).
Figure 3- Comparison of mean levels of big ET-1 among histopathological grades of oral squamous cell carcinoma (OSCC) 
cases using independent t-test
Figure 2- Intergroup and intragroup comparison of mean levels of big ET-1 among clinical stages of oral squamous 
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DISCUSSION
Oral cavity cancer is predominantly a disease 
of middle-aged men as nearly 95% of carcinomas 
occur after the age of 4533. In the present study, the 
age of the OSCC patients ranged from 27-72 years 
with a mean value of 54.68±12.95 years. Peak 
incidence was seen in the 7th decade of life. Similar 
trend was observed in the studies of Bhurgri, et al.9 
(2006) with a peak incidence of oral cancer in the 
7th decade of life. Although the risk of developing 
cancer increases with age, in recent years, the 
incidence of oral cancer have increased in younger 
ages11. In the present study, similar trend was seen 
in 11 out of 40 (27.5%) patients that were below 
or equal to 45 years (4 of them being females and 
7 males). Also 9 out of 11 such patients were in 
stage III+IV, being correlated with the aggressive 
presentation at the time of the report. Which is in 
accordance with previous studies in which younger 
patients were seen as holders of the disease in its 
advanced stage22.
The endothelin axis (endothelins and their 
receptors) performs key physiological functions 
in normal tissue, which includes the modulation 
of the vasomotor tone, tissue differentiation, 
development, cell proliferation and hormone 
production26. Endothelin-1 (ET-1) is a predominant 
and the most relevant biologically isoform among 
endothelins7. The mature endothelin-1 peptide and 
the 2.5 kDa protein are generated by a cascade of 
enzymatic cleavage of the initial preproendothelin-1 
gene product through stages of proendothelin-1 
and big endothelin-1 (big ET-1)27. The ET-1 has 
short plasma half-life (about 1.5 minutes) and low 
circulating levels which dif¿cult the measurement in 
plasma or serum23. So circulating levels of plasma 
or serum big ET-1 (precursor) being a stable 
peptide with plasma half life of 30 minutes may 
serve as a sensitive indicator of endothelin system 
activation23. The ET-1 levels can be measured in 
different body Àuids like human plasma, saliva, 
cerebro-spinal Àuid, urine, pericardial Àuid, breast 
milk, and amniotic Àuid even if the levels vary25. 
Although salivary levels of ET-1 were reported as 
higher than serum levels in oral cancer, it failed to 
show positive correlation with disease activity16,28.
Epithelially derived tumors exhibit heterogeneity 
in expression of endothelin-1 receptors8. The 
ETAR dominant cancer (e.g. prostate and ovarian 
cancer), the ETBR dominant cancer (e.g. melanoma) 
or the ETAR and the ETBR double receptor cancer 
(e.g. colon and lung cancer) are three categories 
that are according to the expression of endothelin 
receptors in cancer26. Cells of OSCC express both 
ETAR and ETBR, which is identical to cells of lung 
and colon cancer6. Those cancers that up-regulate 
ETAR, probably using ET-1 as a direct growth 
factor for cancer cells while those that up-regulate 
ETBR and probably use ET-1 predominantly as 
an activator of cells associated to tumor, such as 
¿broblasts, endothelial cells, and macrophages8,20. 
The up-regulation of ETA receptors by ET-1 in OSCC 
implicate ET-1 as a growth factor for tumor cells 
and suggests its role right from tumor initiation6,19. 
These ¿ndings present serum endothelin-1 as a 
promising biomarker for OSCC.
On the assessment of the levels of serum big 
ET-1 in cases and controls of OSCC, the mean of the 
serum level of big ET-1 was found to be 4.47±1.54 
pg/ml and 1.57±0.48 pg/ml respectively. The 
mean big ET-1 level was significantly higher 
(p<0.0001) in the cases of OSCC compared to 
that in the control group. Elevated levels of serum 
big ET-1have been noted in various nonmalignant 
and malignant diseases7. However, patients in the 
present study did not have any other systemic 
disease and were age and sex matched with 
controls. Thus, the increased level of serum big 
ET-1 may be attributed to the oral malignant 
process. Similarly elevated serum/plasma big ET-1 
levels were found in hepatocellular carcinoma, 
primary colon cancer, basal cell carcinoma, non-
small cell lung cancer, nasopharyngeal carcinoma 
and esophageal cancer patients in comparison to 
healthy individuals4,5,17,18,23,32. Some studies also 
indicated a decrease in serum or plasma levels 
of big ET-1 after tumor resection, attributing the 
increased levels to tumor load18,31.
The trend in the mean of the big ET-1 
concentrations among OSCC stages implied 
progressively increasing levels. By comparing it, 
ANOVA revealed a signi¿cantly different mean of 
the big ET-1 concentrations among OSCC stages 
(Table 1, Figure 2). These ¿ndings are in accordance 
with previous studies, in which serum levels of 
ET-1 are correlated with clinical stages of colorectal 
adenocarcinoma, esophageal cancer, and colon 
cancer1,18,29. However, one study failed to show 
signi¿cant associations between the plasma big 
ET-1 level in the advanced stage of nasopharyngeal 
carcinoma cases and in the overall stage of cancer23.
While comparing the levels serum big ET-1 
among histopathological grades, levels increased 
with the histopathological grade of the disease. But 
the difference in the mean levels of serum big ET-1 
between cases of grade I of OSCC and of grade II 
of OSCC was not statistically signi¿cant (p=0.727) 
(Table 1, Figure 3). Positive correlation found 
between ET-1 expression and poor histological 
differentiation or grade in breast cancer and colon 
cancer is in accordance with these results1,30. 
However, one study reported lack of correlation 
between plasma levels of big ET-1 and the degree 
of histologic differentiation in esophageal cancer18.
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CONCLUSION
By exploring the presence of biomarkers those 
do not require the tumor tissue to detect them, but 
are secreted by cancer cells into the blood stream 
will not only facilitate an easy detection, but will also 
be a candidate for population based screening. In 
accordance with this, the levels of serum big ET-1 
can be used as an adjunctive serological marker for 
the diagnosis of OSCC and may provide further help 
in prognostic information and disease monitoring. 
However, prospective studies on a larger sample 
are needed to substantiate our ¿ndings before 
¿rm conclusions on the utility of these markers be 
drawn in the diagnosis and prognostic assessment 
of oral cancers.
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